Hereditary Angioedema (HAE) Clinical Trial
Official title:
Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration
Verified date | July 2023 |
Source | Takeda |
Contact | Takeda Contact |
Phone | +1-877-825-3327 |
medinfoUS[@]takeda.com | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time. Exclusion Criteria - None |
Country | Name | City | State |
---|---|---|---|
Japan | Takeda selected site | Tokyo | T |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE) | An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product. An adverse event does not necessarily have a causal relationship with the intervention. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | 12 Months | |
Secondary | Number of Angioedema Attacks | Number of angioedema attacks during the study will be assessed. | 12 Months | |
Secondary | Angioedema Quality of life (AE-QoL) Questionnaire | The AE-QoL questionnaire is a self-administered validated instrument to assess health related (HR)QoL among participants with recurrent angioedema (including HAE). The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fear/shame, and nutrition) and each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often). | 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02865720 -
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT04861090 -
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
|
||
Recruiting |
NCT05489640 -
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
|
||
Completed |
NCT02584959 -
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
|
Phase 3 | |
Completed |
NCT01826916 -
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
|
Phase 2 | |
Completed |
NCT04057131 -
FIRAZYR General Drug Use-Results Survey (Japan)
|
||
Recruiting |
NCT05819775 -
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
|
Phase 3 | |
Completed |
NCT02741596 -
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
Completed |
NCT02093923 -
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
|
Phase 1 | |
Completed |
NCT01541423 -
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
|
||
Completed |
NCT03845400 -
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
|
||
Completed |
NCT02586805 -
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
Completed |
NCT02052141 -
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
|
Phase 3 | |
Completed |
NCT03888755 -
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
|
Phase 3 | |
Recruiting |
NCT05147181 -
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
|
||
Recruiting |
NCT05469789 -
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
|
||
Completed |
NCT05460325 -
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT01095510 -
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
|
Phase 2 | |
Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
Withdrawn |
NCT01253382 -
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
|
Phase 2/Phase 3 |